The approval was based on data from the POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of ...

Briumvi significantly outperformed Aubagio at reducing disease activity in people with highly active relapsing forms of MS, a ...

The U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.

After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis (PsA). | After ...

When Jon and Dayla Culp received the news that their six-year-old Labrador retriever, Clarice, had a malignant tumor near her left wrist, the couple was devastated. Dayla had lost her sister, Darcy ...

The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets - ...

In the province of West Sumatra, Indonesia, in the early hours of Monday, March 9, 2026, Mount Marapi registered a powerful eruption. Major update in search for missing Gus One type of drinking water ...

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...

While "seborrheic dermatitis" (seb derm) may not be a household name, one of its most common visible symptoms—flakes that may ...